Category: Business

Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018. The studies examined the use of OMIDRIA in both routine and complex cataract surgery cases perf

Ophthalmology Pipeline Database 2018: Conjunctivitis, Glaucoma, Diabetic Retinopathy, Myasthenia Gravis, Dry Eye Syndrome, Age-related Macular Degeneration, and Cataract – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Pipeline Database – 2018” report has been added to ResearchAndMarkets.com’s offering. Ophthalmology Pipeline Highlights Database – 2018, provides most up-to-date information on key pipeline products in the gl…

IDE Pivotal Trial Results for Glaukos’ iStent inject® Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery

SAN CLEMENTE, Calif. & WASHINGTON–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that two-year U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent inject® Trabecular Micro-Bypass System achieved a statistically significant reduction in unmedicated diurnal intraocul

Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Congress in Washington, D.C., April 13-17, 2018. The four presentations are scheduled as follows: Saturday, April 14: 1:41 PM – 1:46 PMWalter E. Washington Convention Center – Room 143AMiosis Prevention

Dr. Nicole R. Fram of Advanced Vision Care to Present on modmed® Ophthalmology at the 2018 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting

BOCA RATON, Fla.–(BUSINESS WIRE)–Specialty-specific health information technology leader Modernizing Medicine® today announced that Nicole R. Fram, M.D. of Advanced Vision Care will present on Sunday, April 15, during the EMR Industry Spotlight Theater at the 2018 ASCRS•ASOA Annual Meeting. Dr. Fram will educate attendees about her successes utilizing the modmed Ophthalmology suite and its intelligent electronic health record (EHR) system, EMA™, including best practices providers can employ u

Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan™

DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Scott Laranjo as Director, Marketing, RoclatanTM, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Laranjo will direct future marketing activities associated w

SERI Lugano: la riboflavina ParaCel scelta dalla FDA per il cross-linking epi-on per cheratocono

LUGANO, Svizzera–(BUSINESS WIRE)–Lo Switzerland Eye Research Institute ha annunciato che, secondo quanto riportato da un comunicato stampa, la rivoluzionaria formulazione a base di ribloflavina transepiteliale nota come ParaCel, frutto della ricerca dell’amministratore delegato e fondatore dell’istituto, il Dr. Roberto Pinelli, è stata scelta dalla FDA insieme a diverse altre per un protocollo di cross-linking del collagene corneale epi-on (senza asportazione dell’epitelio corneale) per i paz

SERI Lugano: ParaCel riboflavine geselecteerd door FDA voor epi-on crosslinking voor keratoconus

LUGANO, Zwitserland–(BUSINESS WIRE)–Het Switzerland Eye Research Institute heeft aangekondigd dat de doorbraakformulering voor transepitheliale riboflavine, bekend als ParaCel, en op basis van het onderzoek van haar CEO en oprichter Roberto Pinelli, MD, door de FDA uit vele inzendingen is geselecteerd voor een behandelprotocol voor epithelial-on corneale collageen crosslinking voor patiënten met progressieve keratoconus, volgens een persbericht. Alle intellectuele eigendomsrechten voor het pr

SERI Lugano: FDA wählt ParaCel Riboflavin für die „Epi-on“-Hornhautquervernetzung zur Behandlung von Keratokonus

LUGANO, Schweiz–(BUSINESS WIRE)–Wie das Switzerland Eye Research Institute bekanntgab, wählte die FDA aus zahlreichen Alternativen die als ParaCel bekannte, bahnbrechende transepitheliale Riboflavinformulierung für die Behandlung von Patienten mit progressivem Keratokonus. ParaCel basiert auf den Resultaten der Forschungsarbeit von Dr. Pinelli, dem Gründer und CEO des Instituts. AVEDRO, Inc., Waltham, Mass. hatte 2011 alle Rechte am geistigen Eigentum erworben, die das Unternehmen zur Herstel

SERI Lugano : La riboflavine ParaCel est sélectionnée par la FDA pour être utilisée dans le cadre du crosslinking epi-on pour le kératocône

LUGANO, Suisse–(BUSINESS WIRE)–Le Switzerland Eye Research Institute a annoncé que la formulation de riboflavine transépithéliale novatrice, connue sous le nom de ParaCel et basée sur la recherche de son président-directeur général et fondateur Roberto Pinelli, MD, avait été sélectionnée parmi un grand nombre d’autres formulations par la FDA (Food and Drug Administration – Agence américaine de contrôle des produits alimentaires et médicamenteux) pour un protocole de crosslinking (CXL) (réticu

The Global Ophthalmic Surgical Instruments Market is Estimated to Reach USD 11.18 Billion by 2022 from USD 8.36 Billion in 2017, at a CAGR of 6.0% – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Surgical Instruments Market – Global Forecast to 2022” report has been added to ResearchAndMarkets.com’s offering. The global ophthalmic surgical instruments market is expected to reach USD 11.18 billion by 2022…